Cell-free Protein Expression Market

Cell-free Protein Expression Market Outlook (2022-2032)

The global cell-free protein expression market is set to record a market value of US$ 224.7 Mn in 2022 and further expand at a CAGR of 6.2%, which indicates positive market growth for the forecast period of 2022-3032. As such, cell-free protein expression demand is set to be valued at around US$ 409 Mn by the end of 2032.

As projected by Persistence Market Research, in 2022, E.coli cell-free protein expression systems are expected to hold a market value of US$ 108.3 Mn, which accounts for nearly 50% of the worldwide cell-free protein expression market.

Cell-free protein expression consumption accounted for approximately 9.7% of the global protein expression market in the year 2021, which was valued at US$ 2.2 Bn.

Demand Outlook for Cell-free Protein Expression (2017-2021) Vs Market Estimates (2022-2032)

The global cell-free protein expression systems market expanded at a CAGR of 4.6% over the last five years (2017-2021).

Demand for cell-free protein expression has increased due to developments in the field of biological sciences. Cell-free protein expression is extensively used in the synthesis of recombinant proteins.

Introduction of novel processes for the production of complex prokaryotic and eukaryotic proteins using a Continuous-Exchange Cell-free (CECF) protein synthesis system has gained popularity in recent times. This approach significantly prolongs reaction lifetime and increases protein yield as compared to conventional batch reactions. The CECF approach promises future prospects for application in large-scale industrial setups, thus driving cell-free protein expression system demand growth.

Manufacturers are focused on cost-effective and rapid protein expression methods. Furthermore, cell-free protein expression companies are focusing on the development of high-yield protein expression systems.

Overall, the global market for cell-free protein expression is expected to expand at a CAGR of 6.2% and record sales worth US$ 409 Mn by the end of 2032.

What are the Opportunities for Cell-free Protein Expression Product Manufacturers?

“Rapid Advancements in Cell-free Protein Expression Systems Driving Market Expansion”

The years ahead are set to witness numerous lucrative opportunities for manufacturers in the cell-free protein expression market across the world. The industry is consolidated by a few key companies manufacturing cell-free protein expression kits.

Robust research initiatives related to cell-free protein production have given rise to the development of various new applications. Several advancements in the cell-free protein expression system market are leading to new applications in the generation of protein libraries for functional genomic studies, customized drug development, and the expression of virus-like particles, among many other applications.

For instance, cell-free protein expression systems allow easy addition of isotope-labeled amino acids in a selective and specific manner, thus facilitating good resolution in protein NMR experiments.

Similarly, in X-ray crystallography, cell-free protein expression in combination with protein-heavy metal derivatives such as selenomethionine helps solve the phase-contrast problem to determine protein structure through Multi-Wavelength Anomalous Diffraction (MAD).

Future applications of cell-free protein expression systems include membrane protein solubilization to solubilize membrane proteins. Supplements can be added directly to the reaction mixture in the form of nanodiscs, detergents, or liposomes (prokaryotic systems and wheat germ systems), or by using endogenous microsomes or proteoliposomes (eukaryotic systems).

Which Factors are Restraining Cell-free Protein Expression Demand?

“Inability to Carry Out Humanized Glycosylation Patterns”

Lack of eukaryotic co- and post-translational modifications is identified as one of the main restraints that will affect the growth of the cell-free protein expression market in the future.

One of the disadvantages of prokaryotic cell-free systems such as E. coli and wheat germ extracts is their inability to carry out humanized glycosylation patterns. In order to produce glycosylated proteins with rabbit reticulocyte systems, a mammalian membrane protein such as canine microsomal membranes needs to be added to the translation mix, but this can lead to decreased overall protein yield and increased cost. Lack of eukaryotic co- and post-translational modifications by cost-effective systems such as E. coli can be a limitation for its application in industrial-level humanized R&D studies.

High cost and short reaction scale is the second restraint that will affect the growth of the cell-free protein expression market. Cell-free systems are generally not practical for large-scale protein expression, as this can be a rather capital-intensive process due to expensive reagent costs such as phosphate chemicals in nucleotide form and secondary energy sources.

Also, the addition of energy and substrate sources in the process can negatively affect cell-free systems due to short reaction scales. A short reaction scale also leads to the limited ability of resultant protein foldings.

Country-wise Insights

Will the U.S. Remain a Leader in Cell-free Protein Expression Systems?

“Favorable Govt. Initiatives & Large Number of Key Players”

In 2021, the U.S. dominated the North American market with more than 93% market value share. Growing incidence of chronic diseases such as cancer, escalating need for targeted and customized medication, existence of significant R&D institutions, and favorable government efforts in the U.S. are key drivers of this huge market.

Additionally, cell-based research is becoming increasingly popular in academia and the biotechnology industry in the United States. Several government efforts have aided the expansion of the cell-free protein expression sector in the U.S. in recent years.

Furthermore, the U.S. has the presence of a large number of key players who are continuously working on the cell-free protein expression synthesis process to develop various recombinant proteins used for the production of pharmaceutical products, protein-based drug delivery, antibodies and enzymes for disease treatment, etc., which is creating array of opportunities in the country.

Which Country Leads the Europe Cell-free Protein Expression Market?

“Huge Presence of Academic & Research Institutes in Germany”

In 2021, Germany accounted for approximately 29.5% market share by value in the European cell-free protein expression market. This is due to the presence of several academic and research institutes in the country.

Government-funded institutes are working on protein synthesis and protein purification-based research activities. Researchers are trying to do more in the protein synthesis field by using cell-free protein expression techniques.

Furthermore, advances in technology have led to the adoption of novel expression elements such as specially designed promoters, allowing for more effective genomic engineering and translation, resulting in enhanced translation efficiency. There are now software-controlled algorithms that can help get higher yield.

• For instance, scientists at the Max Planck Institute of Biochemistry in Martinsried generated a system that is able to regenerate parts of its own DNA and protein building blocks.

Category-wise Insights

Which Product is Driving High Market Growth?

“E. Coli Cell-free Protein Expression Systems High in Demand”

Out of all the products, the E. coli cell-free protein expression systems dominated this market with 48.2% market share by value in 2021, with sales of around US$ 102.8 Mn. E. coli lysates is one of the most practical and commercially preferred lysate due to higher protein yield and cost-effectiveness.

In recombinant technology, E. coli-based systems are utilized for a variety of biological therapeutics, including insulin. Continuous usage has enabled investigation into the interactions and tolerability of E. coli-based systems' by-products.

Is Any Cell-free Protein Expression Mode Hugely Popular?

“Continuous Flow Cell-free Protein Expression Mode Bringing in Greater Returns”

The continuous flow expression mode is widely used in cell-free protein expression, and accounted for around 71.1% market share value in 2021.

Continuous flow expression allows to continuously feed solutions in the reaction chamber, while the protein of interest and other by-products are filtered out in continuous flow without any disruptions. This expression mode allows the continuous synthesis of cell-free protein expression without any interruptions, thereby driving its popularity.

What is the Impact of COVID-19 on This industry?

The COVID-19 pandemic and resulting lockdowns had a catastrophic impact on most sectors across the world. The healthcare industry experienced an overhaul during this period. Many pharmaceutical, biotechnological, and medical device manufacturers experienced both, positive and negative impacts of the pandemic.

As the world was continuously facing the effects of COVID-19, researchers were turning to synthetic biology, particularly in cell-free protein expression systems, to develop new tools, vaccines, and treatments for COVID-19 patients. As a result, there was a positive impact on the market. Cell-free protein expression was widely used for the development of various treatments.

• For instance, scientists from the North-western University, U.S., developed a high-throughput, cell-free, automated screening platform to rapidly identify anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies.
• Researchers from the University of Trento and the University of Alberta developed colorimetric detection of SARS-CoV-2 viral RNA by an in-vitro transcription/translation assay by using cell-free protein expression techniques.

Competitive Landscape:

• In December 2021, Thermo Fisher Scientific, a world leader in serving science, announced the acquisition of PPD, Inc., a leading global provider of clinical research services to the biopharma and biotech industry, for US$ 17.4 Bn.
• In May 2021, New England Biolabs, Inc., a leading supplier of life science reagents, announced that it had entered into an agreement to acquire Fluorogenics Limited (FGL), a lyophilization R&D service company based in the U.K.
• In April 2019, Takara Bio Inc. announced that it has started joint research on the new development of the CAR gene therapy with a group led by Dr. Hiroshi Shiku, Professor at the Mie University Graduate School of Medicine (Mie University).

Cell-free Protein Expression Market Report Scope

Key Segments of Cell-free Protein Expression Industry Survey

Cell-free Protein Expression Market by Product:

• E.coli Cell-free Protein Expression Systems
• Rabbit Reticulocytes Cell-free Protein Expression Systems
• Wheat Germ Cell-free Protein Expression Systems
• Insect Cells Cell-free Protein Expression Systems
• Mammalian Cell-free Protein Expression Systems

Cell-free Protein Expression Market by Application:

• Enzyme Engineering
• Protein Labelling
• Protein-Protein Interaction
• Protein Purification

Cell-free Protein Expression Market by Expression Mode:

• Continuous Flow Expression
• Batch Expression

Cell-free Protein Expression Market by End User:

• Biotechnological Companies
• Pharmaceutical Companies
• Contract Research Organizations
• Academic and Research Institutes

Cell-free Protein Expression Market by Region:

• North America Cell-free Protein Expression Market
• Latin America Cell-free Protein Expression Market
• Europe Cell-free Protein Expression Market
• East Asia Cell-free Protein Expression Market
• South Asia Cell-free Protein Expression Market
• Oceania Cell-free Protein Expression Market
• Middle East & Africa Cell-free Protein Expression Market

To know more about delivery timeline for this report Contact Sales